CAPOX VERSUS MFOLFOX AS ADJUVANT CHEMOTHERAPY IN PATIENTS WITH STAGE 3 COLON CANCER: A COST-EFFECTIVENESS STUDY

被引：0
|
作者：
Abuloha, S. [1 ]
Li, P. [1 ]
Bian, J. [1 ]
Guo, Y. [1 ]
Shao, H. [1 ]
机构：
[1] Univ Florida, Gainesville, FL USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE189
引用
收藏
页码：S370 / S370
页数：1
相关论文
共 50 条
  • [21] Model-based effectiveness and cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy in Dutch stage II colon cancer patients
    Jongeneel, Gabrielle
    Greuter, Marjolein J. E.
    van Erning, Felice N.
    Koopman, Miriam
    Vink, Geraldine R.
    Punt, Cornelis J. A.
    Coupe, Veerle M. H.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [22] Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer
    Loree, Jonathan M.
    Sha, Aaron
    Soleimani, Maryam
    Kennecke, Hagen F.
    Ho, Maria Y.
    Cheung, Winson Y.
    Mulder, Karen E.
    Abadi, Shirin
    Spratlin, Jennifer L.
    Gill, Sharlene
    CLINICAL COLORECTAL CANCER, 2018, 17 (02) : 156 - 163
  • [23] Innovative chemotherapies for stage III colon cancer: A cost-effectiveness study
    Koperna, T
    Semmler, D
    HEPATO-GASTROENTEROLOGY, 2003, 50 (54) : 1903 - 1909
  • [24] A Japanese multicenter phase II study of adjuvant chemotherapy with mFOLFOX6/CAPOX for stage III colon cancer treatment after D2/D3 lymphadenectomy
    Kazuhiko Yoshimatsu
    Keiichiro Ishibashi
    Keiji Koda
    Hajime Yokomizo
    Noritaka Oda
    Mitsuru Oshiro
    Hiroyuki Kato
    Masatoshi Oya
    Hideo Nakajima
    Shinji Ooki
    Hiroshi Maekawa
    Toshio Matsunami
    Masahiro Tsubaki
    Takeshi Yamada
    Michiya Kobayashi
    Kohji Tanakaya
    Masaru Yokoyama
    Hideyuki Ishida
    Surgery Today, 2019, 49 : 498 - 506
  • [25] A Japanese multicenter phase II study of adjuvant chemotherapy with mFOLFOX6/CAPOX for stage III colon cancer treatment after D2/D3 lymphadenectomy
    Yoshimatsu, Kazuhiko
    Ishibashi, Keiichiro
    Koda, Keiji
    Yokomizo, Hajime
    Oda, Noritaka
    Oshiro, Mitsuru
    Kato, Hiroyuki
    Oya, Masatoshi
    Nakajima, Hideo
    Ooki, Shinji
    Maekawa, Hiroshi
    Matsunami, Toshio
    Tsubaki, Masahiro
    Yamada, Takeshi
    Kobayashi, Michiya
    Tanakaya, Kohji
    Yokoyama, Masaru
    Ishida, Hideyuki
    SURGERY TODAY, 2019, 49 (06) : 498 - 506
  • [26] Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer
    Brooks, Gabriel A.
    Tapp, Stephanie
    Daly, Allan T.
    Busam, Jonathan A.
    Tosteson, Anna N. A.
    CLINICAL COLORECTAL CANCER, 2022, 21 (03) : E189 - E195
  • [27] Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada
    Attard, C. L.
    Maroun, J. A.
    Alloul, K.
    Grima, D. T.
    Bernard, L. M.
    CURRENT ONCOLOGY, 2010, 17 (01) : 11 - 18
  • [28] Survival impact of CAPOX versus FOLFOX in the adjuvant treatment of stage III colon cancer.
    Loree, Jonathan M.
    Sha, Aaron
    Soleimani, Maryam
    Ho, Maria Yi
    Kennecke, Hagen F.
    Cheung, Winson Y.
    Mulder, Karen E.
    Abadi, Shirin
    Spratlin, Jennifer L.
    Gill, Sharlene
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [29] Adjuvant chemotherapy for stage III colon cancer patients
    Balakrishnan, L
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (11) : 1496 - 1496
  • [30] Model-based evaluation of the cost effectiveness of 3versus6 months' adjuvant chemotherapy in high-risk stage II colon cancer patients
    Jongeneel, Gabrielle
    Greuter, Marjolein J. E.
    van Erning, Felice N.
    Koopman, Miriam
    Vink, Geraldine R.
    Punt, Cornelis J. A.
    Coupe, Veerle M. H.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2020, 13
12345